Substrates for Drug Delivery Device and Methods of Preparing and Use
An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.
1 .- 16 . (canceled)
17 . An assembly for use in a condensation aerosol device comprising a metal substrate comprising a metal-oxide enriched exterior surface, the metal substrate selected from the group consisting of steel, stainless steel, aluminum, chromium, copper, iron, titanium, conducting ceramics, and alloys of thermally conducting metal and a drug composition film on the metal-oxide enriched exterior surface, where the film thickness and metal-oxide enriched exterior surface are such that an aerosol formed by vaporizing the drug
composition by heating the metal substrate and condensing the vaporized drug composition contains 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film.
18 . The assembly of claim 17 , further comprising a heat source for supplying heat to said metal substrate to produce a substrate temperature greater than 250° C. and to substantially volatilize the drug composition film from the metal substrate in a period of 2 seconds or less.
19 . The assembly of claim 17 , wherein the film comprises a thickness between 0.05 and 20 microns.
20 . The assembly of claim 17 , wherein the film comprises a therapeutically effective dose of a drug when the drug composition is administered in aerosol form.
21 . The assembly of claim 17 , wherein the metal substrate comprises steel, aluminum, titanium or copper.
22 . The assembly of claim 17 , wherein the metal substrate is oxidatively and/or chemically less reactive at temperatures over 300° C.
23 . The assembly of claim 17 , wherein the metal-oxide enriched exterior surface comprises silicon oxide, iron oxide, chromium oxide, molybdenum oxide, manganese oxide, titanium oxide and/or aluminum oxide.
24 . The assembly of claim 17 , wherein the metal-oxide enriched exterior surface comprises a protective overcoat of a material selected from the group consisting of zirconium oxide, silicon oxide, aluminum oxide, aluminum nitride, and silicon carbide.
25 . The assembly of claim 17 , wherein the metal-oxide enriched exterior surface is a protective overcoat of an inert metal.
26 . The assembly of claim 25 , wherein the inert metal is gold and/or platinum.
27 . The assembly of claim 17 , wherein when the drug composition film is, vaporized and condensed to form aerosol particles, under selected conditions that lead to at least 50% recovery of drug composition in the aerosol, the aerosol produced exhibits less than about 10% by weight drug degradation products.
28 . A drug-supply assembly made by a process comprising:
providing a metal substrate having an exterior surface, the metal substrate selected from the group consisting of steel, stainless steel, aluminum, chromium, copper, iron, titanium, conducting ceramics, and alloys of thermally conducting metal;
treating the exterior surface of the metal substrate to result in a metal-oxide enriched exterior surface; and
coating at least a portion of the metal-oxide enriched exterior surface of the metal substrate with a drug compound to generate a film.
29 . The drug-supply assembly of claim 28 , wherein the treating is by contacting the metal substrate with a chemical that oxidizes the exterior surface.
30 . The drug-supply assembly of claim 28 , wherein the treating is by heating the metal substrate to oxidize the exterior surface.
31 . The drug-supply assembly of claim 28 , wherein the exterior surface is treated with an overcoat of an oxidation resistant material.
32 . The drug-supply assembly of claim 31 , wherein the overcoat is formed by physical vapor deposition, chemical vapor deposition, Electron Beam Deposition; sputtering, ion assisted depositions, electroplating, dip coating, spray coating, and/or sol-gel deposition.
33 . The drug-supply assembly of claim 29 , wherein the chemical is an acid.
34 . The drug-supply assembly of claim 29 , wherein the chemical is a base.
35 . The drug-supply assembly of claim 30 , wherein the heating is at 350° C. for 6 hours.
36 .- 43 . (canceled)